Neurology prior auth for MS medications: what your team needs to know right now

If you work in a neurology practice or handle RCM for one, you already know that prior authorizations for multiple sclerosis medications are among the most labor-intensive, documentation-heavy requests in the specialty. Drugs like Ocrevus, Kesimpta, Mavenclad, Tysabri, and other high-efficacy agents are high-cost specialty drugs, and payers manage them closely. If your team isn't prepared, you'll spend a lot of time chasing denials that were preventable.

What payers commonly require for MS therapies

Requirements differ by plan and by benefit (infused drugs such as Ocrevus and Tysabri usually go through the medical benefit, self-injected and oral drugs through the pharmacy benefit), so pull the plan's current policy for the specific drug. Established patients can face a new authorization mid-therapy when they switch plans or when an employer changes its pharmacy benefit contract.

What to check for:

• Step therapy. Some plans require documented trial and failure of a preferred agent, such as an interferon beta or glatiramer acetate, before approving another oral or infused therapy, and some apply it to a stable patient who is new to the plan.
• MRI recency. Policies may specify how recent the imaging must be, for the initial request and for re-authorization. Check the window in the plan's policy rather than assuming one.
• Time-limited approvals. Approvals carry an end date, so your team re-fights the same battles at each renewal. Record the end date of every approval.
• Specialty pharmacy channel restrictions. Plans may require a specific specialty pharmacy. If the PA doesn't specify the approved dispenser correctly, you'll get a rejection that looks clinical but is purely administrative.

Medicare Advantage plans add another layer. Original Medicare does not apply step therapy to Part B drugs, but Medicare Advantage plans may, for Part B drugs such as infused DMTs, apply it only to new administrations, using a lookback period of at least 365 days (42 CFR 422.136). If the patient received the drug within that lookback period, the next dose is not a new administration, so document every prior administration, especially when the patient is new to the plan. Self-administered DMTs covered under Part D follow the Part D plan's formulary rules, which can include step therapy. These rules still catch practices off guard when a patient ages into an MA plan.

Building a documentation package that actually holds up

Most denials are won or lost before they happen. The difference between a first-submission approval and a two-week appeals fight usually comes down to whether your documentation package anticipated the payer's specific criteria.

For MS medications, your PA submission should routinely include:

• A complete treatment history. Not just the current medication, but every DMT the patient has ever been on, why they stopped (relapse, intolerance, side effects), and what the clinical response was.
• Current neurological exam findings. EDSS score if your neurologist documents it, along with cognitive and functional status notes.
• MRI reports. Both the narrative and key images if your portal allows it. Don't limit it to the most recent scan; include comparative imaging that shows disease activity over time.
• Lab results relevant to the specific drug. JC virus antibody index for Tysabri, lymphocyte counts for Mavenclad, and the hepatitis B screening and quantitative serum immunoglobulins that the Ocrevus and Kesimpta labels call for before starting treatment.
• A clear physician attestation. A narrative statement from the neurologist explaining why this medication for this patient at this time. Generic templated letters get flagged.

One thing that's easy to overlook: if your patient tried and failed an interferon or glatiramer acetate in the past, even years ago, document that explicitly. Payers use step therapy as a denial reason, but they can't enforce it if the patient already completed the step. That history needs to be front and center in the submission.

Handling the step therapy problem

Step therapy for MS is genuinely contentious. The American Academy of Neurology's 2018 practice guideline on disease-modifying therapies, which the AAN reaffirmed in 2024, recommends that clinicians prescribe alemtuzumab, fingolimod or natalizumab for people with highly active MS (guideline summary). A plan's step therapy rules don't always line up with that guidance.

If you're facing a step therapy denial for a patient your neurologist believes needs a high-efficacy DMT from the start, here's a workable path:

1. Request a peer-to-peer immediately. Don't wait for the formal appeal timeline to run out. A conversation between your neurologist and the plan's reviewing physician can move faster than a written appeal.
2. Cite the exception criteria specifically. Plan policies often list step therapy exceptions, such as a documented contraindication, prior failure, or clinical urgency. Find those criteria in the plan's coverage policy and write directly to them. Also check whether your state has a step therapy exception law that applies to insured plans.
3. Use published clinical evidence. Cite the guideline statements and peer-reviewed studies that fit this patient, chosen by the neurologist, rather than just asserting "medically necessary." Confirm each citation says what the letter claims before it goes out.
4. Document urgency carefully. Two or more relapses in the past year, or imaging showing significant new lesion burden, is an urgency argument. Make it explicitly.

A drafting tool can cut the time your billing team spends staring at a blank document. EZAppeal drafts appeal and prior-authorization letters in a few minutes, citing the payer's policy when one is on file, for your team to review and send. The clinical argument and the evidence behind it still come from your neurologist.

Re-authorization: don't get caught off guard

The annual re-auth cycle for MS medications looks manageable on paper and becomes a crisis in practice. With a panel of 50 or more MS patients on specialty medications, you could easily have five to ten re-auth deadlines in a single month.

Set up a tracking system, whether that's a field in your EHR, a shared spreadsheet, or your practice management software, that flags re-auth due dates at least 60 days out. That's not excessive. Some payers take weeks to process even non-urgent requests, and a medication gap while you're waiting can mean a relapse with real consequences for the patient.

A few practical notes on re-auths:

• Always pull the current coverage policy before submitting. Formulary tier placements and step therapy requirements change at annual benefit resets.
• Confirm the specialty pharmacy assignment hasn't changed, especially for patients on MA plans.
• If a patient's insurance changed since the last auth, treat it as a brand-new submission, not a renewal.

Keep your process current

MS prior auth isn't getting simpler. The practices that handle it best aren't necessarily the ones with the largest billing departments. They're the ones with solid documentation habits, proactive tracking, and a clear escalation path when something gets denied.

Start with your tracking system. Know your deadlines. Build your documentation templates around what payers are actually asking for in 2026, not what they asked for three years ago. When you get a denial, respond fast and respond specifically; generic appeals rarely work for high-cost specialty drugs.

Your neurologists are doing the clinical work. Your job is to make sure the payer doesn't interrupt it.